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Abstract
Background: Fourteen-membered ring macrolides have been effective in reducing chronic airway inflammation
and also preventing lung injury and fibrosis in bleomycin-challenged mice via anti-inflammatory effects. EM703 is
a new derivative of erythromycin (EM) without the bactericidal effects. We investigated the anti-inflammatory and
antifibrotic effects of EM703 in an experimental model of bleomycin-induced lung injury and subsequent fibrosis
in mice.
Methods: Seven-week-old male ICR mice were used. All experiments used eight mice/group, unless otherwise
noted in the figure legends. Bleomycin was administered intravenously to the mice on day 0. EM703 was orally
administered daily to mice. All groups were examined for cell populations in the bronchoalveolar lavage (BAL)
fluid and for induction of messenger RNA (mRNA) of Smad3 and Smad4 in the lung tissues by reverse
transcriptase (RT)-polymerase chainreaction (PCR) on day 7. Fibroblastic foci were assessed histologically, and
the hydroxyproline content was chemically determined in the lung tissues on day 28. We performed assay of
proliferation and soluble collagen production, and examined the induction of mRNA of Smad3 and Smad4 by RT-
PCR in murine lung fibroblast cell line MLg2908. We also examined Smad3, Smad4 and phosphorylated Smad2/3
(p-Smad2/3) protein assay by western blotting in MLg2908.
Results: Bleomycin-induced lung fibrosis, and the infiltration of macrophages and neutrophils into the airspace
were inhibited by EM703. The expression of Smad3 and Smad4 mRNA was clearly attenuated by bleomycin, but
was recovered by EM703. EM703 also inhibited fibroblast proliferation and the collagen production in lung
fibroblasts induced by Transforming growth factor-beta (TGF-β). The expression of Smad3 and Smad4 mRNA in
murine lung fibroblasts disappeared due to TGF-β, but was recovered by EM703. EM703 inhibited the expression
of p-Smad2/3 and Smad4 protein in murine lung fibroblasts induced by TGF-β.
Conclusion: These findings suggest that EM703 improves bleomycin-induced pulmonary fibrosis in mice by
actions of anti-inflammation and regulation of TGF-β signaling in lung fibroblasts.
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Background
Idiopathic pulmonary fibrosis (IPF) is a devastating dis-
ease with a five-year survival rate of less than 50% [1,2].
No treatments currently available improve the survival
rate of patients with IPF, and novel therapeutic strategies
are required.
Macrolides have been reported to improve the survival of
patients with diffuse panbronchiolitis (DPB) and cystic
fibrosis via anti-inflammatory effects [3,4]. We previously
reported the preventive effects of 14-membered ring mac-
rolides (14-MRMLs) in an animal experimental model of
bleomycin-induced acute lung injury and subsequent
fibrosis, which were mediated by anti-inflammatory
mechanisms of action [5,6]. 
Recent publications have suggested novel treatment para-
digms based on a more complete understanding of the
pathogenesis of pulmonary fibrosis [7]. The development
of pulmonary fibrosis is thought to include two phases: a
persistent inflammatory phase and a sequential fibrotic
phase [8]. Although the pathogenesis of pulmonary fibro-
sis remains unclear, many investigators have found that
neutrophil-mediated lung injury occurring in the acute
inflammatory phase plays an important role in the pro-
gression of interstitial pneumonia [9-11]. Fibroblast pro-
liferation and extracellular matrix accumulation play a
critical role in the subsequent fibrogenic process [1,12-
14]. TGF-β plays a key role in the development of idio-
pathic pulmonary fibrosis [1,12-17] and in experimental
animal models of pulmonary fibrosis [18-25], and TGF-β
intercellular signaling from the cell membrane to the
nucleus occurs through Smad proteins [26].
Macrolides have been reported to inhibit neutrophil-
induced inflammation [3,5,6], and to inhibit the growth
of nasal fibroblasts [27]. Bleomycin-induced lung injury
and subsequent fibrosis in animals is a widely used exper-
imental model of acute lung injury and fibrosis in
humans [5,6,18-23,28-30]. EM703 is a new 12-mem-
bered ring macrolide derivative of erythromycin (Figure
1) prepared by the Kitasato Institute for Life Sciences in
Kitasato University http://www.lisci.kitasato-u.ac.jp/
main/index2.html without antibacterial effects [31]. It has
recently been reported not only EM-A, but also EM703
suppressed the activation of nuclear factor (NF)-κB and
the production of interleukin-8, demonstrating that the
anti-inflammatory action of the macrolide is independent
of its antibacterial activity [32]. We therefore investigated
the effects of EM703 using an experimental model of ble-
omycin-induced acute lung inflammation and subse-
quent fibrosis in mice.
In this study, we found that EM703 has anti-inflammatory
effects, as do 14-MRMLs, and found a new antifibrotic
effect of EM703 in an experimental model of bleomycin-
induced pulmonary fibrosis in mice. Our results suggest
that the new antifibrotic effect of EM703 through the
mechanisms of action of EM703 in the inhibition of
The structure of the erythromycin A (EM-A) and erythromycin 703 (EM703) was provided by the Kitasato Institute for Life Sci- ences at Kitasato University Figure 1
The structure of the erythromycin A (EM-A) and erythromycin 703 (EM703) was provided by the Kitasato Institute for Life Sci-
ences at Kitasato University.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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Smad-mediated TGF-β signal transduction in murine lung
fibroblasts.
Materials and methods
Mice and reagents
Seven-week-old male ICR mice (Nippon CLEA; Tokyo,
Japan) weighing 30 g each on average were randomly
assigned to groups. All experiments used eight mice/
group, unless otherwise noted in the figure legends. Bleo-
mycin (Nippon Kayaku; Tokyo, Japan) was dissolved in
normal saline solution (NS) and administered intrave-
nously to ICR mice at a dosageof 100 mg/kg body weight
(0.3 ml per mouse). EM703 (Kitasato Institute for Life Sci-
ences, Tokyo, Japan) at 75 mg/kg body weight was sus-
pended in 5% gum arabic (AG) (Wako Pure Chemical
Industries; Tokyo, Japan) at 0.3 ml per mouse and orally
administered by force with a microtube daily to ICR mice.
Schedule and evaluation of early-phase inflammation
NS was administered intravenously to the mice treated
with NS alone (day 0). Bleomycin was administered intra-
venously to mice treated with bleomycin alone and bleo-
mycin plus treatment with EM703 (day 0). AG was orally
administered daily to mice of the NS-alone and bleomy-
cin-alone groups from day -3 until the time of death.
EM703 was administered daily to the EM703-treated
groups from day -3 until the time of death. The mice in all
groups were sacrificed under etheranesthesia on day 7
after bleomycin or NS injection. All groups were exam-
ined for cell populations in the BAL fluid and for induc-
The number of macrophages (a) and neutrophils (b) in BAL fluid on day 7 after bleomycin injection in ICR mice (n = 8) Figure 2
The number of macrophages (a) and neutrophils (b) in BAL fluid on day 7 after bleomycin injection in ICR mice (n = 8). ##P < 
0.01, significantly different from NS-treated group; **P < 0.01, significantly different from bleomycin-alone-treated group. The 
values are means, and the bars are SD.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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tion of mRNA of Smad3 and Smad4 in the lung tissues by
RT-PCR on day 7 after bleomycin or NS injection.
Schedule and process of evaluation of late-phase fibrosis
The bleomycin-untreated groups included the NS-treated
group [group 1] and the EM703-alone group [group 2].
The bleomycin-treated groups included bleomycin alone
[group 3], bleomycin plus pretreatment with EM703 (day
-3 to day 13) [group 4], and bleomycin plus post-treat-
ment with EM703 (day 3 to day 20) [group 5]. NS was
administered intravenously to the bleomycin-untreated
mice (day 0). Bleomycin was administered intravenously
to the bleomycin-treated mice (day0). AG was orally
administered daily to the mice of groups 1 and 3 (day -3
to day 27). EM703 was orally administered dailyto the
mice of group 2 (day -3 to day 27) and those of groups 4
(day -3 to day 13) and 5 (day 3 to day 20). The mice in all
groups were sacrificed under etheranesthesia on day 28
after bleomycin or NS injection. Fibroticfoci were assessed
histologically in the left lung tissues, and the hydroxypro-
line content in the right lung tissues was chemically deter-
mined.
Histological analysis
For histological examination, 10% formalin-fixed lung
tissues were embedded in paraffin. The paraffin sections
were stained with either hematoxylin and eosin (HE) or
Masson Trichrome (MT), and systematically scanned with
a light microscope (OLYMPUS AX80, Tokyo, Japan). We
compared the severity of interstitial fibrosis among the
groups using the Ashcroft score [33].
Hydroxyproline measurement
The total collagen content of the right lung was deter-
mined by hydroxyproline (HOP) assay [34]. After acid
hydrolysis of the right lung with 12N HCL at 100°C for 20
hours in a sealed glass tube (Iwaki Tokyo, Japan), the
HOP content was determined by high-performance liquid
chromatography (HPLC).
Analysis of BAL fluid
BAL fluid was obtained by the injection of 1 ml saline
(three times, total 3 ml) followed by gentle aspiration of
the fluid from the right and left lungs after securing an
intratracheal catheter within a trachea. With this catheter,
the ratios of the recovery of lavage fluid ranged from 70%
to 80% and did not significantly differ among the groups.
The total numbers of cells in the BAL fluid were counted
with a hemocytometer. For differential counts of leuko-
cytes in the BAL fluid, cytospin smear slides were prepared
(Labsystems Japan) and stained with Giemsa solution
(Merck Japan). Differential cell counts were performed on
200 cells per smear.
Pathologic features of lung tissues (Masson Trichrome stain)  on day 28 after bleomycin injection in ICR mice Figure 3
Pathologic features of lung tissues (Masson Trichrome stain) 
on day 28 after bleomycin injection in ICR mice. These pho-
tographs show typical results. NS: NS-treated group; BLM: 
bleomycin-alone-treated group; BLM/EM703: bleomycin-plus-
EM703-treated group. The scale is 200 µm.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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Cell cultures
A murine lung fibroblast cell line, MLg2908 (ATCC, CCL-
206), originating from ddY mice was maintained in
Roswell Park Memorial Institute (RPMI1640, Immuno-
Biological Laboratories Gunma, Japan) with 10% fetal
calf serum (FCS, Eguitech-BIO, INC. Kerrville, TX). Cul-
tures of it were grown in a 5% CO2 humidified atmos-
phere at 37°C. The cell groups tested included those of
group 1 (control), group 2 [presence of TGF-β (TGF-β1,
BD Biosciences, Bedford, MA) alone], and group 3 (pres-
ence of TGF-β and treatment with EM703).
Assay of proliferation of murine lung fibroblast cell line
Lung fibroblast cells were suspended at 5 × 104/ml in
RPMI1640 with 10% FCS and plated in 96-well plates at
100 µl per well in a 5% CO2 humidified atmosphere at
37°C for incubation for 24 hr. The medium was changed
to serum-free Dulbecco's Modified Eagle's Medium
(DMEM, GIBCO™, Grand Island, NY, USA) in all groups,
EM703 was added at various final concentrations for
group 3 incubation for 24 hr. Thereafter, TGF-β was added
at various final concentrations for group 2 and 3 incuba-
tion for 24 hr again. Each group's cells were incubated
with a Cell Counting Kit-8 (DOJINDO; Tokyo, Japan) at
37°C for 3 hr. OD (450 nm) values were measured on a
microplate reader (BIO-RAD Model 3550, Tokyo, Japan).
Assay of soluble collagen production by lung fibroblast cell 
line
Lung fibroblast cells were suspended at 5 × 104/ml in
RPMI1640 with 10% FCS and plated in 24-well plates at
1 ml per well and incubated in a 5% CO2 humidified
atmosphere at 37°C. After 24 hr of incubation, the
medium was changed to serum-free DMEM in all groups,
Histopathologic assessment of pulmonary fibrosis on day 28 after bleomycin injection in ICR mice by the Ashcroft score (n =  8) Figure 4
Histopathologic assessment of pulmonary fibrosis on day 28 after bleomycin injection in ICR mice by the Ashcroft score (n = 
8) (a). Comparison of hydroxyproline contents of lung tissues on day 28 after bleomycin injection in ICR mice (n = 8) (b). pre: 
EM703-pretreated group (day – 3 to day 13); post: EM703-post-treated group (day 3 to day 20). #P < 0.05, ##P < 0.01, signifi-
cantly different from NS-treated group; *P < 0.05, significantly different from bleomycin-alone-treated group. The values are 
means, and the bars are SD.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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and EM703 (5 µg/ml) was added for group 3 incubation
for 24 hr. Thereafter, TGF-β (5 ng/ml) was added for
group 2 and 3, followed by incubation for 24 hr again.
The cells of each group were then washed once and resus-
pended to 1 × 105 cells/ml in serum-free DMEM and
plated in 24-well plates at 1 ml per well for incubation.
After 24 hr of incubation, the supernatants were collected
and measured for collagen concentration with a soluble
collagen assay kit (Biocolor Ltd., UK).
Cell cultures for the expression of Smad3 and Smad4 
mRNA and protein assay
The cells of group 3 were divided into three subgroups as
follows: group 3a: presence of TGF-β and pre-treatment
with EM703; group 3b: presence of TGF-βand syn-treat-
ment with EM703; and group 3c: presence of TGF-β and
post-treatment with EM703. Lung fibroblast cells were
suspended at 2 × 104/ml in RPMI1640 with 10% FCS and
plated in 24-well plates at 1 ml per well for incubation in
a 5% CO2 humidified atmosphere at 37°C. After 48-hr of
incubation, the medium was changed to serum-free
DMEM, and EM703 (5 µg/ml) was added for group 3a,
with incubation continued for 24 hr. Thereafter, TGF-β (5
ng/ml) was added to the cells of groups 2 and 3 (a, b, c).
EM703 (5 µg/ml) was simultaneously added to the cells of
group 3b. After 24 hr of incubation, EM703 (5 µg/ml) was
added for group 3c, followed by incubation for an addi-
tional 24 hr. Each cell culture was examined for the
expression of mRNA of Smad3 and Smad4 by RT-PCR and
for expression of Smad3 and Smad4 protein assay by west-
ern blotting.
Cell cultures for the expression of p-Smad2/3 protein assay
The cell groups tested included those of the control, the
presence of TGF-β alone, and the presence of TGF-β and
pre-treatment with EM703. Conducting the cell cultures
and treatment with EM703 before the presence of TGF-β
used the same method as the Smad3 and Smad4 protein
assay in group 3a. The cells were cultured in the presence
of TGF-β (5 ng/ml) for 15 min and 12 hr. Followed by the
Effect of TGF-β on the proliferation of MLg 2908 Figure 5
Effect of TGF-β on the proliferation of MLg 2908 (a), and effect of EM703 on the proliferation of MLg 2908 induced by TGF-β 
(b). #P < 0.05, significantly different from without-TGF-β group; *P < 0.05, significantly different from only-TGF-β-presence 
group. The results are expressed as mean ± SD of 8 replicate wells.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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presence of TGF-β, the cells were collected and the expres-
sion of p-Smad2/3 protein was examined by western blot-
ting.
RT-PCR
Total RNA was extracted from each specimen of lung tis-
sue (in vivo) and lung fibroblast cells (in vitro) using ISO-
GEN (Nippon GENE; Tokyo, Japan). The methods of RNA
extraction and RT-PCR used have been previously
described [6,35]. For the amplification of the desired
cDNA, the following gene-specific primers were
used[36,37]. Glucose-6-phosphate dehydroge-
nase(G6PD) was measured as an internal control [38].
Smad3: sense 5'-CTGGCTACCTGAGTGAAGATGGAGA-
3',
antisense 5'-AAAGACCTCCCCTCCGATGTAGTAG-3'
Smad4: sense 5'-GTATAATGCCACCAGTACCACCAAC-3',
antisense 5'-TGACCCAAGCAAAAGCGATCTCCTC -3'
G6PD: sense 5'-TAGGAATTCATCATCATGGGTGCATCG-
3'
antisense 5'-TAGAAGCTTGTTTGCGGATGT-
CAGCCACTGT-3'
The PCR products were electrophoresed on 2% agarose
gels, stained with ethidium bromide, and observed with
ultraviolet transillumination. Intensity analysis of the
bands was performed with Adobe Photoshop 6.0 (Adobe
Systems; Tokyo, Japan), with the expression of Smad3
mRNA indicated by the number of white pixel areas.
Western blotting analysis
Western blotting was used for the measurement of Smad3,
Smad4 and p-Smad2/3 protein assay protein in lung
fibroblast cell line MLg2908. Total protein 100 µg was
separated by 10% SDS-PAGE. Transfer to polyvinylidene
difluoride membranes by a blot appliance (AE-6677P,
ATTO CORPORATION, Tokyo, Japan) was performed
according to the manufacturer's instructions. After having
been blocked with 5% skim milk (Snow Brand Milk Pro-
duction, Japan), the membrane was incubated with anti-
Smad3 antibody (sc-8332, Santa Cruz Biotechnology, Inc.
USA; rabbit polyclonal antibody, dilution 1/200) for 1 hr.
The membrane was washed, and primary antibody was
detected using alkaline phosphatase-conjugated affin-
ipure goat anti-rabbit IgG (Jackson ImmunoResearch Lab-
oratories, Inc. USA; dilution 1/10000) incubated for 1 hr.
After having washed the membrane, the Smad3 protein
band was visualized using an alkaline phosphatase sub-
strate. Smad4 protein was detected by anti-Smad4 anti-
body (sc-7966, Santa Cruz Biotechnology, Inc. USA;
mouse monoclonal antibody, dilution 1/100), and pri-
mary antibody was detected using alkaline phosphatase-
conjugated affinipure goat anti-mouse IgG+IgM (Jackson
ImmunoResearch Laboratories, Inc. USA; dilution 1/
10000). Smad4 protein was detected using the same
method as Smad3. p-Smad2/3 protein was detected by
anti-p-Smad2/3 (sc-11769, Santa Cruz Biotechnology,
Inc. USA; goat polyclonal antibody, dilution 1/100), and
primary antibody was detected using donkey anti-goat
IgG horseradish peroxidase (HRP) (sc-2056, Santa Cruz
Biotechnology, Inc. USA; dilution 1/5000). P-Smad2/3
protein was detected by the chemiluminescence system
(Amersham Biosciences ECL plus Western Blotting Detec-
tion System).
Statistical analysis
Statistical analysis of the data was performed using Stat
Mate III software (ATMS DIGITALS Medical Station,
Tokyo, Japan). Comparisons between groups were per-
formed using one-way ANOVA followed by the Newman-
Effects of EM703 on the collagen production of MLg2908  induced by TGF-β Figure 6
Effects of EM703 on the collagen production of MLg2908 
induced by TGF-β. TGF-β: 5 ng/ml, EM703: 5 µg/ml. ##P < 
0.01, significantly different from without-TGF-β group; *P < 
0.05, significantly different from only-TGF-β-presence group. 
The results are expressed as the mean ± SD of 8 replicate 
wells.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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Keuls test. P values of less than 0.05 were considered sig-
nificant.
Results
Changes in cell number in BAL fluid
Numbersof macrophages and neutrophils in BAL fluid
were significantly increased on day 7 after bleomycin
injection. The increases in number of macrophages and
neutrophils in BAL fluid were significantly attenuated by
EM703 (Figure 2).
Histopathologic assessment
Bleomycin-induced pulmonary fibrosis was significantly
inhibited by treatment with EM703 on day 28 after bleo-
mycin injection in ICRmice. A typical picture of the atten-
uation of fibrosis is shown in Figure 3. Of the groups
These photographs show typical results Figure 7
These photographs show typical results. Each density of PCR products was measured using Adobe Photoshop 6.0. G6PD was 
measured as an internal control. The ratio of each Smad molecule against G6PD is shown by a histogram. bp: base pair. (a) 
Effects of EM703 on the expression of Smad3 and Smad4 mRNA in lung tissue on day 7 after bleomycin injection in ICR mice 
(n = 3). #P < 0.05, ##P < 0.01, significantly different from NS-treated group; **P < 0.01, *P < 0.05, significantly different from 
bleomycin-alone-treated group. The values are means, and the bars are SD. (b) Expression of Smad3 and Smad4 mRNA in 
MLg2908. TGF-β: 5 ng/ml, EM703: 5 µg/ml. Each group as described in Materials and Methods: Cell cultures for the expression 
of mRNA and protein assay.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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treated with EM703, the Ashcroft scores were significantly
reduced compared to those in the bleomycin-alone group
(Figure 4a). The administration of EM703 alone resulted
in no remarkable changes in the results of histopathologic
assessment of lung tissue.
Hydroxyproline content in lung tissue
The concentration of hydroxyproline on day 28 after ble-
omycin injection was significantly higher in the bleomy-
cin-alone group than in the NS-alone group. Of the
groups treated with EM703, the hydroxyproline content
was significantly reduced compared to that in the bleomy-
cin-alone group. The administration of EM703 alone
resulted in no remarkable changes in the hydroxyproline
content of the lung tissue (Figure 4b).
Assay of proliferation of MLg2908
TGF-β significantly increased MLg2908 proliferation (Fig-
ure 5a). The proliferation of MLg2908 induced by TGF-β
was significantly inhibited by EM703 (Figure 5b).
Assay of soluble collagen production by MLg2908
TGF-β significantly increased the production of soluble
collagen by MLg2908 cells. The increase in the measured
concentration of soluble collagen induced by TGF-β was
significantly inhibited by EM703 (Figure 6).
Expression of Smad3 and Smad4 mRNA in lung tissues
The expression of Smad3 mRNA was eliminated by bleo-
mycin, but recovered to control level by treatment with
EM703 on day 7 after bleomycin injection. The expression
of Smad4 mRNA was attenuated by bleomycin, but recov-
ered to a higher control level by treatment with EM703 on
day 7 after bleomycin injection (Figure 7a).
Expression of Smad3 and Smad4 mRNA in MLg2908
The expression of Smad3 and Smad4 mRNA was com-
pletely eliminated by the addition of TGF-β. The elimina-
tion of the expression of Smad3 and Smad4 mRNA by
TGF-β was reversed to higher than the control level by pre-
treatment with EM703, but was not recovered by syn-
treatment or post-treatment with EM703 (Figure 7b).
Expression of Smad3, Smad4 and p-Smad2/3 protein in 
MLg2908
The expression of Smad3 protein in murine lung fibrob-
lasts was not changed by TGF-β. The expression of p-
Smad2/3 protein was increased by TGF-β. The increased
expression of p-Smad2/3 protein by TGF-β exposure for
15 min was remarkably inhibited by pre-treatment with
EM703, but the increased expression of p-Smad2/3 pro-
tein by TGF-β exposure for 12 hr was not inhibited by pre-
treatment with EM703. The expression of Smad4 protein
Expression of Smad3, Smad4 and p-Smad2/3 protein in MLg2908 by western blotting Figure 8
Expression of Smad3, Smad4 and p-Smad2/3 protein in MLg2908 by western blotting. TGF-β: 5 ng/ml, EM703: 5 µg/ml. Each 
group as described in Materials and Methods: Cell cultures for the expression of mRNA and protein assay.Respiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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was increased by TGF-β. The increased expression of
Smad4 protein by TGF-β was inhibited by pre-treatment
with EM703, but not inhibited by syn-treatment or post-
treatment with EM703 (Figure 8).
Discussion
We previously reported that 14-MRMLs inhibited the
induction of vascular cell adhesion molecule 1 mRNA and
leukocyte migration in the early inflammatoryphase,
thereby preventing lung injury and fibrosis in bleomycin-
challenged mice [6]. In the present study, we investigated
the effects of EM703 – a new derivative of EM in the same
experimental model in both the acute inflammatory
phase and sequential fibrotic phase in mice.
Initially, to evaluate the effects of EM703 on the inflam-
matory phase, we investigated bleomycin-induced
changes in the cell populations in BAL fluid on day 7 after
bleomycin injection. The increase in the number of mac-
rophages and neutrophils in the BAL fluidon day 7 after
bleomycin injection was significantly attenuated by
EM703 (Figure 2). Not only EM-A, but also EM703, sup-
pressed the activation of NF-κB and the production of
interleukin-8 [32]. Taken together, his finding suggests
the possibility that EM703 also inhibits the migration of
neutrophils and macrophages into the airspace, which
would be an important anti-inflammatory mechanism in
this model in addition to those possessed by 14-MRMLs
[6].
To evaluate the effects of EM703 in the fibroticphase, we
further investigated bleomycin-induced histopathologic
changes and changes in hydroxyproline content in the
lung tissues on day 28 after bleomycin injection, which is
within the fibrotic phase. Bleomycin-induced pulmonary
fibrosis on day 28 was significantly inhibited by treatment
with EM703 (Figures 3, 4). The effectof EM703 on bleo-
mycin-induced pulmonary fibrosis in mice appeared
owing to the attenuation of inflammatory cell infiltration
such as neutrophil and macrophage migration due to
EM703, resulting in the inhibition of lung injury and sub-
sequent fibrosis. This may be a mechanism of the antifi-
brotic effects of EM703.
In a previous study, the effectiveness of pre-treatment with
14-MRMLs (beginning 3 days before bleomycin injection
to 13 days after bleomycin injection) was significantly
stronger than that of post-treatment (beginning 3 days to
13 days after bleomycin injection)with 14-MRMLs [6]. In
this study, the effectiveness of post-treatment with EM703
(beginning 3 days to 20 days after bleomycin injection)
was almost equal to that of pre-treatment with EM703
(beginning 3 days before bleomycin injection to 13 days
after bleomycin injection) (Figures 4). Practically, the
numbers of macrophages and neutrophils returned to
control levels at13 days after bleomycin injection [6]. The
post-treatment with EM703 also significantly inhibited
bleomycin-induced pulmonary fibrosis, suggesting that
the mechanisms of action of EM703 against bleomycin-
induced pulmonary fibrosis in mice may involve not only
anti-inflammatory effects but also anti-fibrotic effects
resulting in the direct attenuation of fibroblast prolifera-
tion.
It has been reported that fibroblast proliferation and
extracellular matrix accumulation play an important role
in the fibrogenic process [1,12-14]. TGF-β plays a key role
in the development of idiopathic pulmonary fibrosis
[1,12-17] and animal experimental modelsof lung fibro-
sis [18-25]. Our recent report suggests that the TGF-β level
was increased in the same bleomycin-challenged mouse
lung fibrosis model as this study [39]. To determine the
mechanisms by which EM703 inhibits bleomycin-
induced pulmonary fibrosis in mice, we further examined
the effects of EM703 on the proliferation of and collagen
production due to murine lung fibroblasts induced by
TGF-β in vitro. Our findings indicated that the prolifera-
tion of murine MLg2908 lung fibroblasts induced by TGF-
β was significantly inhibited by EM703 (Figure 5), and
that the increase in the production of soluble collagen by
TGF-β was significantly inhibited by EM703 (Figure 6).
The mechanisms of inhibition by EM703 of bleomycin-
induced pulmonary fibrosis in mice may involve the inhi-
bition of TGF-β signaling, mediating fibroblast prolifera-
tion and extracellular matrix production.
TGF-β signaling from the cell membrane to the nucleus
occurs via Smad proteins [26]. Smad2 and Smad3 are
structurally highly similar and mediate TGF-β signals.
Smad4 is distantly related to Smad2 and Smad3, and
forms a heteromeric complex with Smad2 after TGF-β or
activin stimulation. TGF-β induces heteromeric com-
plexes of Smad2, 3 and 4, and their concomitant translo-
cation to the nucleus, which is required for efficient TGF-
β signal transduction [40]. Smad3 contributes to bleomy-
cin-induced lung injury [41], and is a major component of
the signal transduction pathway leading to fibrogenesis
[42,43]. It has been reported that the expression of Smad3
mRNA was down-regulated at an early stage of inflamma-
tory injury during bleomycin-induced pulmonary fibro-
sis, and the expression of Smad2 mRNA remained
unchanged after bleomycin administration [44].
The most common theory of the pathogenesis of idio-
pathicpulmonary fibrosis is that the disease process
begins with an 'alveolitis,' characterized by the accumula-
tion of inflammatory cells. Neutrophils and mononuclear
cells accumulate, and concomitant cytokines (like TGF-β)
are released to stimulate fibroblast proliferation. Fibrob-
lasts then migrate into areas of acute lung injury and areRespiratory Research 2006, 7:16 http://respiratory-research.com/content/7/1/16
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stimulated to secrete collagen and other matrix proteins
[[1,8] and [12]].
Therefore, we examined the expression of Smad3 and
Smad4 in lung tissue on early-phase day 7 after bleomycin
injection. The results obtained were consistent with the
reported data [44], that is, the expression of Smad3 mRNA
was down-regulated at an early stage of inflammatory
injury during bleomycin-induced pulmonary fibrosis
(Figure 7a, Lane 2). The Smad4 mRNA was also down-reg-
ulated by bleomycin in this model (Figure 7a, Lane 2).
The decrease in the expression of Smad3 and Smad4
mRNA by bleomycin was reversed to control level or
higher than the control level by treatment with EM703 on
day 7 after bleomycin injection (Figure 7a, Lane 3).
We further examined the regulation of the expression
ofSmad3 and Smad4 mRNA by TGF-β in murine lung
fibroblasts in vitro. The results showed that the expression
of Smad3 and Smad4 mRNA was completely eliminated
by TGF-β (Figure 7b, Lane 2). It has been demonstrated
that there occurs an immediate translocation of Smad3
protein from the cytoplasm to the nucleus and a delayed
down-regulation of Smad3 mRNA by TGF-β in lung
fibroblasts [44]. Our results showed that the elimination
of the expression of Smad3 and Smad4 mRNA by TGF-β
(Figure 7b, Lane 2) was reversed to higher than the control
level by pre-treatment with EM703 (Figure 7b, Lane 3),
but was not recovered by syn-treatment (Figure 7b, Lane
4) or post-treatment (Figure 7b, Lane 5) with EM703.
The expression of Smad3 protein in murine lung fibrob-
lasts was not changed by TGF-β. The expression of p-
Smad2/3 and Smad4 proteins was remarkably increased
by TGF-β. The increased expression of Smad4 protein was
remarkably inhibited by pre-treatment with EM703, but
was not inhibited by syn-treatment or post-treatment with
EM703. The increased expression of p-Smad2/3 by TGF-β
exposure for 15 min was remarkably inhibited by EM703,
but the increased expression of p-Smad2/3 by TGF-β
exposure for 12 hr was not inhibited by EM703 (Figure 8).
Both TGF-β receptor type I and type II are indispensable
for TGF-β signaling [45-47]. We thus considered the pos-
sibility that the mechanisms by which EM703 inhibits
TGF-β signal transduction in fibroblasts involve TGF-β
receptors.
Recent work indicates that fibroblasts respond to TGF-β
independently of Smad2/3 phosphorylation, and non-
Smad TGF-β signaling pathways are also quite active in
the bleomycin fibrosis models [48]. These are the results
of studies mainly investigating the action of TGF-β2. TGF-
β1, -β2, and -β3 are differentially expressed during bleomy-
cin-induced lung fibrosis [23]. In this study, we investi-
gated the effects of EM703 on the action of TGF-β1 in the
murin lung fibroblasts. TGF-β1 plays a key role in the
pathogenesis of pulmonary fibrosis, and the Smad3 path-
way is involved in fibrogenesis [41-44].
Many investigators have found that fibroblasts migrate
into areas of acute lung injury [8], in which fibroblastic
foci represent an active form of fibroblasts [12]. TGF-β
participates not only in the late phase but also the active
early phase of acute lung injury [49-51]. The down-regu-
lation of Smad3 in the early stage of inflammation and
during the reparative phase was in contrast to the expres-
sion of collagen [44]. In this study, since the decrease in
the expression ofSmad3 mRNA by bleomycin was
reversed to higher than the control level by treatment with
EM703 on day 7 after bleomycin injection, we emphasize
that the antifibrotic effects of EM703 will be exhibited
both in early inflammatory phase and more effectively in
the reparative phase (Figure 4).
At present, there are no proven treatments for idiopathic
pulmonary fibrosis. New strategies for such treatment
have, however, been discussed, including the use of anti-
inflammatory agents such as ONO5046 [52], antifibrotic
agents such as pirfenidone [53,54] and immune modula-
tors such as interferon gamma [55]. Many investigators
have found that effective therapeutic strategies might
include the modification of fibroblast replication, the
modification of matrix deposition [1,14], the blocking of
TGF-β [23,25,49], and the disruption of Smad3-mediated
TGF-β signal transduction [41,42].
In this study, we found that EM703 improved bleomycin-
induced pulmonary fibrosis in mice by inhibiting fibrob-
last TGF-β signal transduction, and clarified the anti-
inflammatory and anti-fibrotic effects of EM703 in the
attenuation of bleomycin-induced pulmonary fibrosis.
Although there is a room for further investigation of the
mechanism of EM703 inhibition of bleomycin-induced
lung fibrosis, we believe that at least the anti-inflamma-
tion action and the signal control action of TGF-β will
work. We found no deaths or abnormal reactions with a
daily administration of 75 mg/kg body weight of EM703
during the experiments. Our results suggest that EM703
may be a promising new, safe agent for the treatment of
pulmonary fibrosis, with both anti-inflammatory and
anti-fibrotic effects.
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